Skip to content

Embecta Corp. EMBC Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Insulet logo
InsuletPODD
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
Medtronic logo
MedtronicMDT
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
ICU Medical logo
ICU MedicalICUI
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX

Other financials

Income statement

See full
Revenue$221.8M-14.4%
Gross profit$127.8M-22.1%
Operating income$35.0M-44.4%
Net income-$4.1M-117%
EPS (diluted)-$0.07-118%

Balance sheet

See full
Cash & equivalents$193.4M-8.9%
Total debt$1.4B-12.5%
Total equity-$626.1M+15.0%
Total assets$1.0B-8.1%

Cash flow

See full
Operating cash flow$31.1M-2.2%
CapEx$500.0K+400%
Free cash flow$30.6M-3.5%

Valuation

See full
Market cap$193.41M-64.3%
Enterprise value$1.37B-24.8%
P/E1.7×-4.8×
P/S0.2×-0.3×

Profitability

See full
Gross margin61.9%-1.6pp
Operating margin25.8%+9.7pp
Net margin10.7%+5.8pp
FCF margin19.6%+16.0pp

Returns & leverage

See full
Return on equity71.9%
Debt / equity
Current ratio2.5×0.0×

Where this comes from

Reported directly by Embecta Corp. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Embecta Corp.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Embecta Corp.'s common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Embecta Corp.'s common stock, shares authorized (in shares)?
Embecta Corp. (EMBC) reported common stock, shares authorized (in shares) of $250M in Q1 2026.
How has Embecta Corp.'s common stock, shares authorized (in shares) changed year-over-year?
Embecta Corp.'s common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $250M to $250M.
What is the long-term trend for Embecta Corp.'s common stock, shares authorized (in shares)?
Over 3 years (2022 to 2025), Embecta Corp.'s common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $250M to $250M.